Your Article Summary
See Latest ArticlesCorcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/02/06
Corcept Therapeutics Incorporated announced that the second of its three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression (PMD) was negative. Study 09 was a randomized, double-blind, placebo-controlled study
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09